Antibodies Against Membrane Protein Targets – Part 2

 

Membrane-bound proteins are attractive drug targets for antibodies and other protein scaffolds, but for the field to advance, fundamental challenges in optimizing antigen quality and presentation, discovery methodologies, protein engineering and target identification must be resolved. This two-part meeting provides a forum in which discovery biologists and protein engineers can come together to discuss next-generation strategies and technologies that will allow antibody-based therapeutics directed against GPCR and ion channel targets to advance into the clinic and beyond. Part 2, Discovery, Characterization and GPCR/Ion Channel Updates, explores developments at the discovery and screening stages and offers focused sessions on each of these target classes.


Preliminary Agenda

DISCOVERY STRATEGIES

Delivering the Best Therapeutic Antibody Molecule by Combination of In Vivo Antibody Discovery with In Vitro Affinity Optimization
Agnieszka Kielczewska, Senior Scientist, Antibody Discovery, Amgen, Canada

Lead Antibody Identification Using Rabbit B Cell Cloning Platform
Tomoyuki Igawa, PhD, Research Head, Chugai Pharmaceuticals, Singapore

RetrogenixUncovering Novel Receptor Targets and Assessing Target Specificity against Human Membrane and Secreted Proteins
Alex Kelly, US Business Development Manager, Retrogenix Limited

THERAPEUTIC DEVELOPMENT FOR GPCRs

Talk Title to be Announced
Trevor Wilkinson, PhD, Associate Director, Antibody Discovery and Protein Engineering, AstraZeneca, United Kingdom

Development of Therapeutic Antibodies Targeting C5aR1
Brian Booth, PhD, Senior Scientist, Drug Discovery, Visterra

THERAPEUTIC DEVELOPMENT FOR ION CHANNELS

 

Controlling Membrane Proteins with Photopharmacology
Dirk Trauner, PhD, Professor, Chemistry, NYU

Targeting Kv1.3 with Biologics: Venom Peptides, Antibodies and Things in Between
Heike Wulff, PhD, Associate Professor, Pharmacology, School of Medicine, University of California, Davis

Modulating the Function of the P2X7 Ion Channel with Antibodies and Nanobodies
Friedrich Koch-Nolte, PhD, Professor, Laboratory of Molecular Immunology, University Medical Center Hamburg-Eppendorf, Germany

Automation of Ion Channel Recordings
Jen Pan, PhD, Director, Translational Neurobiology, Stanley Center at the Broad Institute

SCREENING AND CHARACTERIZATION

Massive Antibody Discovery used to Probe Structure-Function Relationships of an Essential Gram-Negative Bacteria Outer Membrane Protein
Steven Rutherford, PhD, Scientist, Genentech

Cell-Based Assays to Characterize Ligands for Chemokine Receptor CXCR4
Tom Van Loy, PhD, Researcher, Rega Institute, K.U. Leuven, Belgium

Talk Title to be Announced
John Blankenship, PhD, Senior Investigator and Group Leader, Library Technologies, Novartis

High Throughput Functional Screening
Mariana Lemos-Duarte, PhD, Postdoctoral Researcher, Icahn School of Medicine at Mount Sinai

Please click here to return to the agenda for Antibodies Against Membrane Protein Targets – Part 1

Part 1 will focus on best practices for antigen preparation, new approaches to antibody generation and the important role of structural modeling and analysis – and track early stage, preclinical and clinical progress in this space.


 

For more details on the conference, please contact:
Kent Simmons

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 207-869-9199
Email: ksimmons@healthtech.com

 

For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286
Email: reymael@healthtech.com